Join the first international survey of people living with HCC
Your fight against liver cancer is your first priority, and only you can know the impact that liver cancer has on your daily life.
But you are also one among tens of thousands of people like yourself, who are fighting a similar battle every day, in every country of the world. In fact, HCC is the fourth most common cancer diagnosed each year and according to the WHO, the second most common cause of cancer deaths worldwide.
Blue Faery has recently joined a special partnership of similar organizations across North America, Asia and Europe in an effort to ask hundreds of men and women like you to share your experiences by responding to the first international survey of people living with HCC. Our hope is the results of this survey will provide doctors and cancer researchers with some of the insights they need to improve liver cancer treatments. Additionally, by sharing your story, we hope to destigmatize the diagnosis of liver cancer.
The survey is online and you can access it from your personal computer at www.hcc-voices.com/us1. Your personal information and opinions will not be shared with anyone. The survey will take approximately 15 – 30 minutes, and it will be available on the web until December 31, 2016.
In addition to Blue Faery, a number of other liver cancer groups are taking part in the survey including the American Liver Foundation, British Liver Trust, Canadian Liver Foundation, European Liver Patients’ Association, Taiwan Liver Cancer Association and a number of liver cancer treatment units in major medical centers around the world. The survey was developed for these organizations by the research company, Strategic Sight, which will analyze the results in collaboration with the Medical Technology Research Group of the London School of Economics, with an unrestricted educational grant from Sirtex.
The results of the survey will be made available early in 2017, in the form of a report from the London School of Economics and the participating liver cancer groups. The survey findings will be made available to liver research organizations, scientific journals and the media.